News Release
2019.09.19
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury
News Release
2019.09.13
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury, at 2019 World Federation of Neurosurgical Societies Special World Congress
News Release
2019.08.30
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury was presented at the Military Health System Research Symposium 2019
News Release
2019.05.15
Bijan Nejadnik, M.D., appointed as Chief Medical Officer of SanBio
News Release
2019.04.25
SB623, an Investigational Product, Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency
News Release
2019.04.17
AANS 2019: SB623 Demonstrated Statistically Significant Improvement in Motor Function Among Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI)
News Release
2019.04.08
SanBio announces SB623 regenerative cell therapy for traumatic brain injury has received Ministry of Health, Labour and Welfare (MHLW) Sakigake designation
News Release
2019.03.29
SanBio to give an encore presentation on the results of a Phase 2 STEMTRA trial regarding the use of regenerative cell medicine SB623 as a treatment for TBI at the 14th Korea–Japan Joint Conference on Surgery for Cerebral Stroke
News Release
2019.03.06
SanBio to announce the results of a Phase 2 STEMTRA trial regarding the use of regenerative cell medicine SB623 as a treatment for TBI at an annual scientific meeting of the American Association of Neurological Surgeons
News Release
2019.02.08
A Message to Patients from CEO Keita Mori regarding Topline Analytical Results of Clinical Trial Announced on January 29, 2019（94KB）
News Release
2025.12.09
SanBio Obtains Partial Change Approval for“AKUUGO🄬 Suspension for Intracranial Implantation”
News Release
2025.12.08
Appointment of Two Corporate Officers in the Quality Compliance & Regulatory Affairs Division and the Production Division
News Release
2025.06.25
Notice Regarding Revision of Expected Approval Timing for Partial Changes to AKUUGO(R)Suspension for Intracranial Implantation
News Release
2025.06.12
Notice of Completion of Application for Partial Change Approval of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2025.05.30
Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association
News Release
2025.05.29
The Results of the Third Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2025.04.18
The Yield Results of the Third Commercial Production Run for AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2025.02.12
Publication of Results of Cell Implantation Location Analysis from Phase 2 Clinical Trial of Vandefitemcel (SB623) in TBI Patients (STEMTRA Trial) in Neurotrauma Reports
News Release
2025.02.06
The Results of the Second Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2025.01.07
Publication of an Article in Molecular Therapy Demonstrates That SB623 ImprovesCortical Excitability in Rats with Focal Cerebral Ischemia
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2026.04.09
Keita Mori, CEO, spoke at “Miyaman’s Venture Talk vol.15: Exploring Brain Regeneration with Mitsuru Miyata and Keita Mori,” hosted by LINK-J (April 9, 2026)
Info
2026.04.03
Keita Mori, CEO, will be a speaker at “Regenerative Medicine EXPO” hosted by RX Japan(2026.5.21)
Info
2025.10.09
Keita Mori, President & CEO, participated as a speaker in the sponsored seminar at “BioJapan 2025” (October 9, 2025)
Info
2025.09.09
Keita Mori, CEO, will be a panelist at “US-Japan Healthcare Connection” hosted by the Japan Society of Northern California (2025.9.19)
Info
2025.01.14
Sawaguchi, Head of Japan Regulatory Affairs & Quality Compliance Japan, will speak at 【Regenerative Medicine Seminar 2024】“Development of Regenerative Medicine Products: Recent Trends in Regenerative Medicine and Other Related Issues” (Vol.5: Quality in Regenerative Medicine Products)” hosted by the Clinical and Translational Research Center (CTR) Keio University Hospital
Info
2024.11.11
MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
